Industry Bodies Urge GMO Exemption For Advanced Therapies In EU
CRISPR/Cas9 Genome Editing Tool Could Be Affected
ATMPs should be treated like COVID-19 products when it comes to the EU rules on genetically modified organisms, say ARM, EFPIA and EuropaBio.
You may also be interested in...
The European Commission’s Pharmaceutical Strategy should end regulatory “carve outs” like the hospital exemptions, and innovate pricing and reimbursement structures, says the Alliance for Regenerative Medicines.
The need to accelerate clinical trials of products for treating and preventing coronavirus has led the EU authorities to propose a more streamlined process for allowing the release of GMO-containing investigational medicinal products into the environment.
Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP
AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.